-
Capital, M&A & Industry Strategy2 weeks agoRoche ADC deal could give Hansoh a path to global expansion: Deals Report
BIOCENTURY | DEALSROCHE ADC DEAL COULD GIVE HANSOH A PATH TO GLOBAL EXPANSION: DEALS REPORTPlus: Gilead, Vir in T cell engager agreement; Merck KGaA/Silence; and more
-
Synthetic Biology, Genomics & Advanced Therapeutics2 weeks agoSilence is golden: Germany-based Merck pays $1.3B for siRNA company
BIOCENTURY | DEALSSILENCE IS GOLDEN: GERMANY-BASED MERCK PAYS $1.3B FOR SIRNA COMPANYAugust readout in polycythemia vera was key driver of the deal
-
Clinical Trials & Development2 weeks agoCould a metabolic lens on mortality reshape clinical trials?
BIOCENTURY | DISCOVERY & TRANSLATIONCOULD A METABOLIC LENS ON MORTALITY RESHAPE CLINICAL TRIALS?The metabolic vulnerability index captures overlooked mortality risk, with stronger predictions of death than...
-
Synthetic Biology, Genomics & Advanced Therapeutics2 weeks agoThe future of RNAi with Arrowhead’s Chris Anzalone on The BioCentury Show
BIOCENTURY | PRODUCT DEVELOPMENTTHE FUTURE OF RNAI WITH ARROWHEAD’S CHRIS ANZALONE ON THE BIOCENTURY SHOWCEO’s view on solving extra-hepatic siRNA delivery and Arrowhead’s future growth opportunities
-
Capital, M&A & Industry Strategy2 weeks agoAftermarket gains for City, Iambic: Public Equity Report
BIOCENTURY | FINANCEAFTERMARKET GAINS FOR CITY, IAMBIC: PUBLIC EQUITY REPORTPlus: Aspen, Bambusa enter NASDAQ queue; financings for Akeso, Verastem, First Tracks and more
-
Drug Discovery & Therapeutics2 weeks agoValuing a preclinical biotech at $50B is a bad idea — a Perspective
BIOCENTURY | EDITOR'S COMMENTARYVALUING A PRECLINICAL BIOTECH AT $50B IS A BAD IDEA — A PERSPECTIVEIf the rumors are true, Isomorphic Labs would require near perfect clinical...
-
Regulatory Intelligence & Drug Approvals2 weeks agoEMA’s CHMP backs RevMed’s first-in-class pancreatic cancer therapy
BIOCENTURY | REGULATIONEMA’S CHMP BACKS REVMED’S FIRST-IN-CLASS PANCREATIC CANCER THERAPYRecommendations follow speedy FDA approvals of the RAS(ON) inhibitor and Lilly’s obesity pill Foundayo orforglipron
-
Regulatory Intelligence & Drug Approvals2 weeks agoFDA signals intent to improve consistency, seek external advice on rare disease therapies
BIOCENTURY | REGULATIONFDA SIGNALS INTENT TO IMPROVE CONSISTENCY, SEEK EXTERNAL ADVICE ON RARE DISEASE THERAPIES‘Catastrophically broken’ agency could struggle to implement reforms, former Acting Commissioner Woodcock...
-
Global Biotechnology & Pharmaceutical Markets2 weeks agoRoche turns to China’s Rona for ALK7-siRNA for selective fat loss
BIOCENTURY | DEALSROCHE TURNS TO CHINA’S RONA FOR ALK7-SIRNA FOR SELECTIVE FAT LOSSChina biotechs fuel a growing RNAi pipeline silencing ALK7 in adipocytes
-
Global Biotechnology & Pharmaceutical Markets2 weeks agoChina’s RNAi pipeline drives dealmaking with the West
BIOCENTURY | DATA BYTECHINA’S RNAI PIPELINE DRIVES DEALMAKING WITH THE WESTCardiometabolic programs lead the dealmaking as China’s developers push delivery beyond the liver
Widespread atropine use fails to sway FDA advisors on Sydnexis data
At least 11 PDUFAs on FDA’s November docket
FDA Grants Accelerated Approval to Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) for Recurrent Respiratory Papillomatosis
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
